Implications of Healthcare Reform: 'No' Will Be Heard is led by Cliff Goodman, PhD, in a panel discussion featuring A. Mark Fendrick, MD, co-editor in chief of The American Journal of Managed Care, John L. Fox, MD, MHA, and Ira M. Klein, MD, MBA, FACP. The panelists determine what it means when a patient says no.
“Implications of Healthcare Reform: ‘No’ Will Be Heard” is led by Cliff Goodman, PhD, in a panel discussion featuring A. Mark Fendrick, MD, co-editor in chief of The American Journal of Managed Care, John L. Fox, MD, MHA, and Ira M. Klein, MD, MBA, FACP. The panelists determine what it means when a patient says “no.”
Dr Fox says that payers don’t want to be in a position that interposes them between patients and providers. “We can’t expect that patients are always going to make rational decisions, but we can certainly expect that patients be afforded the opportunity to make their choices known, and to have their choices respected.” Dr Fox adds that the challenge is that all too often, patients don’t have the opportunity to make their decisions known until it is too late.
Dr Ira Klein agrees with Dr Fox, saying that the “no” conversation between providers and payers is sometimes necessary. “The patients are often, and this is not their fault, not fully informed as to what it is that is requested, and what the repercussions and ramifications are,” says Dr Klein. “How people feel about care affects utilization, and for them to feel anything about care, they have to understand care and there has to be a little bit more transparency. So it doesn’t mean we’re going to take all our patients and turn them into amateur oncologists, it just means that they should have access to a little bit more understanding about what it is going to happen to them from the beginning, the middle, and the end.” He adds that how and when you say no is related to the stakeholders at hand.
Dr Fendrick then asks, “When does no really mean no?” He suggests that having the “no” discussion, which is actually pretty rare, to shift from “easier to get, to less to get.” He says that it is important for all stakeholders to ration harmful care, or care that is known to be harmful.
The panelists continue discussions on issues including the impact of healthcare reform and payment delivery on patient engagement, and how “no” might lead to problems such as underuse.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Powles Highlights “Transformative” Benefit of EV Plus Pembro While Sharing Long-Term Data for EV-302
February 15th 2025The lead investigator for EV-302 said not long ago, survival of 12 to 14 months in this type of bladder cancer was considered an achievement; in this study, median overall survival was 34 months after treatment with enfortumab vedotin (EV) and pembrolizumab (pembro).
Read More
Analysis Looks at Benefits, Toxicity of ADC Combinations in Advanced Bladder Cancer
February 15th 2025City of Hope's Salvador Jaime-Casas, MD, discusses a systematic review of recent trials examining objective response rate and adverse events of antibody-drug conjugate (ADC) combinations in advanced urothelial cancer.
Read More